Opioid antagonists

Opioid Analgesics

Opioid Abuse and Rehabilitation

Prenatal Genetic Counseling and Evaluation

The Asymptomatic Patient With Abnormal Laboratory Test Results

Many Docs Still Don't Understand Opioid Dependence

Misperceptions about opioid dependence and how to treat it persist for both the public and primary care physicians, new research suggests. Medscape Medical News

BioDelivery Sciences Primed To Grab Its Share Of The $1.5 Billion Opioid Market

By Scott Matusow:These days, prescription drugs have become a source for legal and illegal abuse. This abuse can lead to a medical diagnosis called opioid dependence, which is when a patient that is a...

Novel Opioid Dependence Pill Gets Patients' Thumbs-Up

Compared with buprenorphine-naloxone sublingual film to treat opioid dependence, a sublingual menthol-flavored tablet has a preferred taste and comparable dissolve time. Medscape Medical News

Titan submits Probuphine NDA under 505(b)(2) for opioid dependence

Titan Pharmaceuticals wants the US FDA's blessing to market Probuphine, a subdermal implant product designed to deliver six months of buprenorphine hydrochloride following a single treatment, as a m...

Cognitive behavioral therapy adds no value to drug treatment for opioid dependence

(Medical Xpress)—In a surprise finding, Yale researchers report that adding cognitive behavioral therapy to the most commonly used drug treatment for opioid dependence does not further reduce illici...

Titan's Implant For Treating Opioid Dependence - FDA Panel Gives A Cautious 'Yes'

Probuphine, a buprenorphine subdermal implant formulation for adults with opioid dependence has been given a green light by an FDA Advisory Committee (Panel). The Panel cited a favorable benefit-risk...

Opioid Analgesia in Mechanically Ventilated Children

Opioid analgesics help to reduce pain, anxiety, and agitation, but may also lead to opioid tolerance, dependence, and more . . . Pediatric Critical Care Medicine

Titan seeks approval for Probuphine

Titan Pharmaceuticals Inc. (OTCBB:TTNP) submitted an NDA to FDA for Probuphine buprenorphine to treat opioid dependence. The company requested Priority Review for the application. The NDA was submitte...

Risks for opioid abuse and dependence among recipients of chronic opioid therapy: Results from the TROUP Study.

OBJECTIVE: To estimate the prevalence of and risk factors for opioid abuse/dependence in long-term users of opioids for chronic pain, including risk factors for opioid abuse/dependence that can potent...

Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system.

ABSTRACT Aims Our study sought to assess the prevalence of and risk factors for opioid drug dependence among out-patients on long-term opioid therapy in a large health-care system. Methods Using elect...

Dependence and Addiction During Chronic Opioid Therapy.

The use of opioids for chronic noncancer pain has increased dramatically over the past 25 years in North America and has been accompanied by a major increase in opioid addiction and overdose deaths....

Opioid dependence.

Dependence on opioids is a multifactorial condition involving genetic and psychosocial factors. There are three stages to treating opioid dependence. Stabilisation is usually by opioid substitution tr...

Opioid modulators for alcohol dependence.

Introduction: Studies have shown that opioid antagonists like naltrexone are efficient in reducing heavy drinking. The neurobiological mechanism by which opioid modulators affect drinking behavior is...